Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research

被引：4

作者：

Ning, Li ^{[1
,2
]}

Xi, Jiahui ^{[1
,2
]}

Zi, Yin ^{[1
,2
]}

Chen, Min ^{[1
,2
]}

Zou, Qingjian ^{[1
,2
]}

Zhou, Xiaoqing ^{[1
,2
]}

Tang, Chengcheng ^{[1
,2
]}

机构：

[1] Wuyi Univ, South China Inst Large Anim Models Biomed, Sch Biotechnol & Hlth Sci, Guangdong Prov Key Lab Large Anim Models Biomed, Jiangmen 529000, Peoples R China

[2] Int Healthcare Innovat Inst Jiangmen, Jiangmen, Peoples R China

来源：

CLINICAL GENETICS | 2023年 / 104卷 / 06期

关键词：

cancer; gene-editing; CRISPR/Cas9; gene therapy; immunotherapy; T-CELLS; CAS9; RIBONUCLEOPROTEIN; GENOMIC DNA; DELIVERY; BASE; IDENTIFICATION; BACTERIA; EFFICACY; REPEATS; SYSTEMS;

D O I：

10.1111/cge.14424

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Cancer, one of the leading causes of death, usually commences and progresses as a result of a series of gene mutations and dysregulation of expression. With the development of clustered regularly interspaced palindromic repeat (CRISPR)/Cas9 gene-editing technology, it is possible to edit and then decode the functions of cancer-related gene mutations, markedly advance the research of biological mechanisms and treatment of cancer. This review summarizes the mechanism and development of CRISPR/Cas9 gene-editing technology in recent years and describes its potential application in cancer-related research, such as the establishment of human tumor disease models, gene therapy and immunotherapy. The challenges and future development directions are highlighted to provide a reference for exploring pathological mechanisms and potential treatment protocols of cancer.

引用

页码：613 / 624

页数：12

共 75 条

[1] Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management [J].

Allemailem, Khaled S. ;

Alsahli, Mohammed A. ;

Almatroudi, Ahmad ;

Alrumaihi, Faris ;

Alkhaleefah, Fahd Khaleefah ;

Rahmani, Arshad Husain ;

Khan, Amjad Ali .

CANCER COMMUNICATIONS, 2022, 42 (12) :1257-1287

[2] Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors [J].

Anzalone, Andrew V. ;

Koblan, Luke W. ;

Liu, David R. .

NATURE BIOTECHNOLOGY, 2020, 38 (07) :824-844

[3] Search-and-replace genome editing without double-strand breaks or donor DNA [J].

Anzalone, Andrew V. ;

Randolph, Peyton B. ;

Davis, Jessie R. ;

Sousa, Alexander A. ;

Koblan, Luke W. ;

Levy, Jonathan M. ;

Chen, Peter J. ;

Wilson, Christopher ;

Newby, Gregory A. ;

Raguram, Aditya ;

Liu, David R. .

NATURE, 2019, 576 (7785) :149-+

[4] An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance [J].

Bester, Assaf C. ;

Lee, Jonathan D. ;

Chavez, Alejandro ;

Lee, Yu-Ru ;

Nachmani, Daphna ;

Vora, Suhani ;

Victor, Joshua ;

Sauvageau, Martin ;

Monteleone, Emanuele ;

Rinn, John L. ;

Provero, Paolo ;

Church, George M. ;

Clohessy, John G. ;

Pandolfi, Pier Paolo .

CELL, 2018, 173 (03) :649-+

[5] Hydrodynamic Gene Delivery and Its Applications in Pharmaceutical Research [J].

Bonamassa, Barbara ;

Hai, Li ;

Liu, Dexi .

PHARMACEUTICAL RESEARCH, 2011, 28 (04) :694-701

[6] Long-term outcomes following CAR T cell therapy: what we know so far [J].

Cappell, Kathryn M. ;

Kochenderfer, James N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (06) :359-371

[7] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition [J].

Cherkassky, Leonid ;

Morello, Aurore ;

Villena-Vargas, Jonathan ;

Feng, Yang ;

Dimitrov, Dimiter S. ;

Jones, David R. ;

Sadelain, Michel ;

Adusumilli, Prasad S. .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) :3130-3144

[8]

Chow Jonathan Tak-Sum, 2020, Fac Rev, V9, P31, DOI 10.12703/r/9-31

[9] Adenovirus: The First Effective In Vivo Gene Delivery Vector [J].

Crystal, Ronald G. .

HUMAN GENE THERAPY, 2014, 25 (01) :3-11

[10] CRISPR gene editing tested in a person [J].

Cyranoski, David .

NATURE, 2016, 539 (7630) :479-479

← 1 2 3 4 5 6 7 8 →